SCHEMBL4837408

SCHEMBL4837408

CC(=O)NC1(c2cccc(F)c2)CCN(CCC2c3ccccc3CCN2C(=O)c2cccc3ccccc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TACR3 P29371 7/20 0.41
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
DRD2 P14416 4/20 0.37
DRD3 P35462 4/20 0.37
NR1D1 P20393 2/20 0.36
MTNR1B P49286 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
NCOR2 Q9Y618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839170 0.92 POLB (0.41) ALDH1A1TACR3DRD2DRD3NR1D1
SCHEMBL4839492 0.92 CYP2C19 (0.49) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4832889 0.91 CYP2C19 (0.48) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4837346 0.90 CYP2C19 (0.47) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4832868 0.89 CYP2C19 (0.46) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4839617 0.88 CYP2C19 (0.44) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4830055 0.88 CYP2C19 (0.49) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4829948 0.87 CYP2C19 (0.46) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4840728 0.86 CYP2C19 (0.50) CYP2C19ALDH1A1TACR3GAAHTT
SCHEMBL4837044 0.86 CYP2C19 (0.47) CYP2C19ALDH1A1TACR3GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 CYP2C19 789/4885ALDH1A1 639/4885TACR3 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.